Weekly Research Analysts’ Ratings Changes for Kura Oncology (KURA)

Kura Oncology (NASDAQ: KURA) recently received a number of ratings updates from brokerages and research firms:

• 5/16/2024 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
• 5/14/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 5/6/2024 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
• 5/3/2024 – Kura Oncology had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
• 5/3/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 4/22/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 4/15/2024 – Kura Oncology was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/3/2024 – Kura Oncology was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.

Kura Oncology Stock Up 0.3 %

KURA stock traded up $0.07 on Monday, reaching $22.24. 487,080 shares of the company traded hands, compared to its average volume of 1,211,275. Kura Oncology, Inc. has a one year low of $7.41 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.67 and a quick ratio of 16.67. The company has a market cap of $1.69 billion, a P/E ratio of -10.25 and a beta of 0.89. The firm has a fifty day simple moving average of $20.55 and a 200-day simple moving average of $17.07.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same quarter in the prior year, the company earned ($0.50) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis. Research analysts anticipate that Kura Oncology, Inc. will post -2.56 earnings per share for the current year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,615 shares of Kura Oncology stock in a transaction on Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the completion of the sale, the insider now owns 68,979 shares of the company’s stock, valued at approximately $1,527,884.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. DekaBank Deutsche Girozentrale boosted its stake in shares of Kura Oncology by 216.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 95,000 shares of the company’s stock worth $1,343,000 after buying an additional 65,000 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Kura Oncology by 18.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 563,421 shares of the company’s stock valued at $5,138,000 after purchasing an additional 86,141 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Kura Oncology by 10.9% during the third quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock valued at $2,387,000 after purchasing an additional 25,677 shares in the last quarter. Jupiter Asset Management Ltd. lifted its position in Kura Oncology by 234.2% during the third quarter. Jupiter Asset Management Ltd. now owns 57,877 shares of the company’s stock valued at $528,000 after purchasing an additional 40,560 shares in the last quarter. Finally, Walleye Capital LLC lifted its position in Kura Oncology by 220.4% during the third quarter. Walleye Capital LLC now owns 264,893 shares of the company’s stock valued at $2,416,000 after purchasing an additional 182,221 shares in the last quarter.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.